Bivalent and Monovalent SARS-CoV-2 Variant Vaccine Boosters Improve coverage of the known Antigenic Landscape: Results of the COVID-19 Variant Immunologic Landscape (COVAIL) Trial

Vaccine protection against COVID-19 wanes over time and has been impacted by the emergence of new variants with increasing escape of neutralization. The COVID-19 Variant Immunologic Landscape (COVAIL) randomized clinical trial (clinicaltrials.gov NCT 05289037) compares the breadth, magnitude and dur...

Descripción completa

Detalles Bibliográficos
Autores principales: Branche, Angela, Rouphael, Nadine, Diemert, David, Falsey, Ann, Losada, Cecilia, Baden, Lindsey (R), Frey, Sharon, Whitaker, Jennifer, Little, Susan, Anderson, Evan, Walter, Emmanuel, Novak, Richard, Rupp, Richard, Jackson, Lisa, Babu, Tara, Kottkamp, Angelica, Luetkemeyer, Annie, Immergluck, Lilly, Presti, Rachel, Backer, Martin, Winokur, Patricia, Mahgoub, Siham, Goepfert, Paul, Fusco, Dahlene, Malkin, Elissa, Bethony, Jeff, Walsh, Edward, Graciaa, Daniel, Samaha, Hady, Sherman, Amy, Walsh, Stephen, Abate, Getahun, Oikonomopoulou, Zacharoula, El Sahly, Hana, Martin, Thomas, Kamidani, Satoshi, Smith, Michael, Ladner, Benjamin, Porterfield, Laura, Dunstan, Maya, Wald, Anna, Davis, Tamia, Atmar, Robert, Mulligan, Mark, Lyke, Kirsten, Posavad, Christine, Meagher, Megan, Stephens, David, Neuzil, Kathleen, Abebe, Kuleni, Hill, Heather, Albert, Jim, Telu, Kalyani, Mu, Jinjian, Lewis, Teri, Giebeig, Lisa, Eaton, Amanda, Netzl, Antonia, Wilks, Sam, Tureli, Sina, Makhene, Mamodikoe, Crandon, Sonja, Montefiori, David, Makowski, Mat, Smith, Derek, Nayak, Seema, Roberts, Paul, Beigel, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10187423/
https://www.ncbi.nlm.nih.gov/pubmed/37205592
http://dx.doi.org/10.21203/rs.3.rs-2653179/v1
Descripción
Sumario:Vaccine protection against COVID-19 wanes over time and has been impacted by the emergence of new variants with increasing escape of neutralization. The COVID-19 Variant Immunologic Landscape (COVAIL) randomized clinical trial (clinicaltrials.gov NCT 05289037) compares the breadth, magnitude and durability of antibody responses induced by a second COVID-19 vaccine boost with mRNA (Moderna mRNA-1273 and Pfizer-BioNTech BNT 162b2), or adjuvanted recombinant protein (Sanofi CoV2 preS DTM-AS03) monovalent or bivalent vaccine candidates targeting ancestral and variant SARS-CoV-2 spike antigens (Beta, Delta and Omicron BA.1). We found that boosting with a variant strain is not associated with loss in neutralization against the ancestral strain. However, while variant vaccines compared to the prototype/wildtype vaccines demonstrated higher neutralizing activity against Omicron BA.1 and BA.4/5 subvariants for up to 3 months after vaccination, neutralizing activity was lower for more recent Omicron subvariants. Our study, incorporating both antigenic distances and serologic landscapes, can provide a framework for objectively guiding decisions for future vaccine updates.

Ejemplares similares